Gensciences starts second FRSW107 Phase 3, adding to a crowded Factor VIII field
The China-only 60-patient trial tests annualized bleed rate against a landscape scored 'challenging,' with no comparator arm and no model read yet on record.
Executive Summary
- Hangzhou Gensciences Biopharmaceutical Co., Ltd. registered a second Phase 3 trial of FRSW107, a recombinant Factor VIII-Fc fusion protein, testing prophylactic dosing in 60 adult and adolescent men with severe hemophilia A in China NCT07684898Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.NCT07684898.
- The trial is single-arm and open-label with no comparator, so a positive annualized bleeding rate result will be hypothesis-generating rather than decision-grade on its own NCT07684898Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.NCT07684898.
- This is the sponsor's second active Phase 3 FRSW107 program, alongside NCT06136507 in pediatric patients, indicating a two-track registrational strategy rather than a single pivotal bet.
- The trial enters a Factor VIII replacement field already occupied by Sanofi, Bayer, CSL Behring, Takeda, Sinocelltech, and BioMarin, with the broader landscape scored 'challenging' at 52/100.
- No AppliedXL model probability exists for this catalyst, so the setup cannot yet be weighed against a calibrated forecast.
The filing
Hangzhou Gensciences Biopharmaceutical Co., Ltd. added a new Phase 3 study to ClinicalTrials.gov on July 6, 2026, registering FRSW107, a recombinant human coagulation Factor VIII-Fc fusion protein, as prophylactic treatment for severe hemophilia A NCT07684898Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.NCT07684898. The trial, NCT07684898, plans to enroll 60 men aged 12 to 65 with confirmed severe disease, defined as Factor VIII activity below 1%, who have at least 150 prior exposure days to Factor VIII products. The study runs only in China, started recruiting on June 12, 2026, and targets a primary completion date of March 9, 2027 NCT07684898Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.NCT07684898.
What it measures
The registered primary endpoint is annualized bleeding rate (ABR), calculated as the number of bleeding episodes during the six-month efficacy evaluation period divided by treatment days over 365.25 NCT07684898Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.NCT07684898. Secondary endpoints span annualized joint bleed rate, Factor VIII trough and recovery levels, immunogenicity against FRSW107 and CHO cell proteins, incidence of Factor VIII inhibitor development, and pharmacokinetic parameters in a subgroup NCT07684898Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.NCT07684898. The design is single-arm and open-label, with no comparator arm disclosed in the registry record. That structure means a favorable ABR result will support the mechanism but cannot establish superiority or non-inferiority against another Factor VIII product on its own.
A second Phase 3, not the first
This is not the sponsor's only late-stage FRSW107 program. Hangzhou Gensciences already runs NCT06136507, a Phase 3 trial of FRSW107 in pediatric patients with severe hemophilia A, which is not yet recruiting and lists a primary completion date of December 31, 2026. Running two concurrent Phase 3 studies for the same molecule, split by age group, points to a label strategy that covers both adult and pediatric prophylaxis rather than a single pivotal trial carrying the whole registrational case.
Sponsor track record
Hangzhou Gensciences has completed five of nine total trials globally with no terminations, a 100% completion rate across its portfolio. That operational record supports confidence the company can execute an enrollment and follow-up plan, but it says nothing about whether FRSW107 will show a competitive bleeding-rate profile once data mature.
A crowded field
FRSW107 enters a Factor VIII replacement landscape with direct comparators already in Phase 3 or Phase 4, including Sanofi's efanesoctocog alfa, Bayer's damoctocog alfa pegol, CSL Behring's lonoctocog alfa, and Sinocelltech's omfiloctocog alfa, plus gene therapy competitors from BioMarin and Pfizer targeting the same Factor VIII biology through a different modality. The broader target-indication landscape carries a challenging score of 52 out of 100, and recent trial activity in Factor VIII has fallen to roughly 3% of its historical volume, a signal of a decelerating rather than expanding field.
What is missing
No results have posted yet for NCT07684898 on ClinicalTrials.gov, and no completed Phase 3 hemophilia A trials for FRSW107 exist to benchmark expected effect size against approved Factor VIII products. No FDA designation or approval history exists for FRSW107, so the drug's regulatory path outside China, if any, remains undefined.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.